Dr. Michael Har-Noy, founder and CEO of Immunovative Therapies Ltd., a biotech company in Israel, discusses CryoStim™, a novel treatment for patients with disseminated metastatic cancer. CryoStim™ combines Immunovative Therapies' proprietary drug AlloStim™ with cryosurgical ablation of a single tumor lesion (either the primary tumor or a metastatic nodule), thus stimulating a tumor-specific immune response which kills cancer cells wherever they are located in the patient's tissue.
Dr. Michael Har-Noy goes on to explain that patients are first infused with a dose of AlloStim™, which is a biologic compound designed to elicit rejection by the patient and, in the process, disable the tumor's immune avoidance mechanism. The rejection of the AlloStim™ cells results in the patient being immune to the drug. The cancer patient then undergoes a cryoablation procedure designed to freeze a piece of accessible tumor. This piece of tumor then dies by the process of necrosis, a mechanism that results in an immune response to clean-up and dispose of the damaged and dead cells. Additional AlloStim™ is injected into the necrotic tumor, resulting in another powerful memory recall immune response to reject this repeated dose of AlloStimTM cells. The combination of these two powerful immune responses educates the patient's immune system to recognize the dead tumor cells as dangerous.
Dr. Michael Har-Noy says that years of immunotherapy trials have shown that the immune system of the cancer patient does not recognize the threat of human cancer cells as well as the rodent immune system does in research models of similar diseases. Dr. Michael Har-Noy goes on to explain that this is why immunotherapy models that work well in rodents fail repeatedly in human trials.
Cancer cells can be destroyed by necrosis through various techniques, such as radiofrequency ablation, cryosurgery, high intensity ultrasound, laser interstitial therapy, and microwave thermotherapy. Dr. Michael Har-Noy points out that only the cryoablation technique leaves tumor proteins, such as heat shock proteins and tumor antigens, intact. The methods other than cryoablation cause protein denaturalization through destruction and fusing of the cellular membranes. Cryoablation is accepted therapy for liver, kidney, lung, prostate, bone, and breast cancers. Dr. Michael Har-Noy explains that cryoablation causes necrotic cell because of cellular damage by ice crystals, resulting in endothelial and vascular injury and ischemia.
Dr. Michael Har-Noy concludes that the presentation of tumor antigens in an inflammatory environment can disable cancer cells' ability to avoid the human immune response. Preliminary test results indicate that CryoStimTM is effective against a wide variety of cancer cell types.